A new possibility: gene-expression-based diagnostics for presymptomatic diagnosis of hospital-acquired infections

Luís F. Moita; Timothy E. Sweeney; Pedro Póvoa

doi:10.1007/s00134-022-06823-w

A new possibility: gene-expression-based diagnostics for presymptomatic diagnosis of hospital-acquired infections

Luís F. Moita, Timothy E. Sweeney, Pedro Póvoa^*

^*Kontaktforfatter

KI, OUH, Forskningsenhed for Klinisk Epidemiologi (Odense)

Publikation: Bidrag til tidsskrift › Leder › peer review

Originalsprog	Engelsk
Tidsskrift	Intensive Care Medicine
Vol/bind	48
Udgave nummer	9
Sider (fra-til)	1206-1207
ISSN	0342-4642
DOI	https://doi.org/10.1007/s00134-022-06823-w
Status	Udgivet - sep. 2022

Bibliografisk note

Funding Information:
LFM—None to declare. TES—employee of and shareholder in Inflammatix, Inc. PP—received fees for lecture from Gilead and Pfizer, consulting from MSD and Sanofi and unrestricted research grant from Abionic.

Dokumenter og links

10.1007/s00134-022-06823-w

Citationsformater

@article{4c86bb500650488ab534e7c3fde90a17,

title = "A new possibility: gene-expression-based diagnostics for presymptomatic diagnosis of hospital-acquired infections",

keywords = "Cross Infection/diagnosis, Hospitals, Humans",

author = "Moita, {Lu{\'i}s F.} and Sweeney, {Timothy E.} and Pedro P{\'o}voa",

note = "Funding Information: LFM—None to declare. TES—employee of and shareholder in Inflammatix, Inc. PP—received fees for lecture from Gilead and Pfizer, consulting from MSD and Sanofi and unrestricted research grant from Abionic. ",

year = "2022",

month = sep,

doi = "10.1007/s00134-022-06823-w",

language = "English",

volume = "48",

pages = "1206--1207",

journal = "Intensive Care Medicine",

issn = "0342-4642",

publisher = "Springer Science+Business Media",

number = "9",

}

TY - JOUR

T1 - A new possibility

T2 - gene-expression-based diagnostics for presymptomatic diagnosis of hospital-acquired infections

AU - Moita, Luís F.

AU - Sweeney, Timothy E.

AU - Póvoa, Pedro

N1 - Funding Information: LFM—None to declare. TES—employee of and shareholder in Inflammatix, Inc. PP—received fees for lecture from Gilead and Pfizer, consulting from MSD and Sanofi and unrestricted research grant from Abionic.

PY - 2022/9

Y1 - 2022/9

KW - Cross Infection/diagnosis

KW - Hospitals

KW - Humans

U2 - 10.1007/s00134-022-06823-w

DO - 10.1007/s00134-022-06823-w

M3 - Editorial

C2 - 35916912

AN - SCOPUS:85135354217

SN - 0342-4642

VL - 48

SP - 1206

EP - 1207

JO - Intensive Care Medicine

JF - Intensive Care Medicine

IS - 9

ER -